| Dr Tracey Bastiaans, DO | |
|
4 Live Oak Ct, Moultrie, GA 31768-6783 | |
| (229) 785-2400 | |
| Not Available |
| Full Name | Dr Tracey Bastiaans |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 11 Years |
| Location | 4 Live Oak Ct, Moultrie, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952749582 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | OT018067 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Colquitt Regional Medical Center | Moultrie, GA | Hospital |
| Entity Name | Sterling Plastic Surgery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982273488 PECOS PAC ID: 6204230071 Enrollment ID: O20210802002977 |
News Archive
According to a new study by British researchers, risk takers stand less chance of getting Parkinson's disease, live longer, and have more friends.
A study published in BioMed Central's open access journal, Arthritis Research & Therapy , found that increased waist circumference and body mass index (BMI) were associated with the risk of both knee and hip joint replacement.
In an effort to improve the accuracy and efficiency of the healthcare supply chain, Siemens Healthcare Diagnostics (Siemens) has published product data including GS1 Global Trade Item Numbers (GTINs) for its entire U.S. product line into the GHX Health ConneXion(SM) data pool.
UC San Francisco is the lead institution on a new seven-year, $17 million multicenter study funded by the National Institutes of Health to determine if certain immune system cells and/or a drug now used for treating rheumatoid arthritis can be effective in improving and maintaining the long-term health of kidney transplant recipients.
According to a new report by iData Research, the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of this market, particularly in the stent-graft and peripheral vascular stent segments. These markets are both expected to exceed $1 billion by 2016.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tracey Bastiaans, DO Po Box 2876, Moultrie, GA 31776-2876 Ph: (229) 891-9131 | Dr Tracey Bastiaans, DO 4 Live Oak Ct, Moultrie, GA 31768-6783 Ph: (229) 785-2400 |
News Archive
According to a new study by British researchers, risk takers stand less chance of getting Parkinson's disease, live longer, and have more friends.
A study published in BioMed Central's open access journal, Arthritis Research & Therapy , found that increased waist circumference and body mass index (BMI) were associated with the risk of both knee and hip joint replacement.
In an effort to improve the accuracy and efficiency of the healthcare supply chain, Siemens Healthcare Diagnostics (Siemens) has published product data including GS1 Global Trade Item Numbers (GTINs) for its entire U.S. product line into the GHX Health ConneXion(SM) data pool.
UC San Francisco is the lead institution on a new seven-year, $17 million multicenter study funded by the National Institutes of Health to determine if certain immune system cells and/or a drug now used for treating rheumatoid arthritis can be effective in improving and maintaining the long-term health of kidney transplant recipients.
According to a new report by iData Research, the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of this market, particularly in the stent-graft and peripheral vascular stent segments. These markets are both expected to exceed $1 billion by 2016.
› Verified 6 days ago